BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tebbe U, Tschöpe C, Wirtz JH, Lokies J, Turgonyi E, Bramlage P, Strunz AM, Lins K, Böhm M. Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF. Clin Res Cardiol 2014;103:665-73. [PMID: 24535376 DOI: 10.1007/s00392-014-0678-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Shah M, Bhalla V, Patnaik S, Maludum O, Lu M, Figueredo VM. Heart failure and the holidays. Clin Res Cardiol 2016;105:865-72. [DOI: 10.1007/s00392-016-0995-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
2 Sarwar CMS, Bhagat AA, Anker SD, Butler J. Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders. Handb Exp Pharmacol 2017;243:537-60. [PMID: 28382468 DOI: 10.1007/164_2017_25] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
3 Jackson JD, Cotton SE, Bruce Wirta S, Proenca CC, Zhang M, Lahoz R, Balas B, Calado FJ. Care pathways and treatment patterns for patients with heart failure in China: results from a cross-sectional survey. Drug Des Devel Ther 2018;12:2311-21. [PMID: 30100706 DOI: 10.2147/DDDT.S166277] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Frankenstein L, Fröhlich H, Cleland JG. Abordaje multidisciplinario en pacientes hospitalizados por insuficiencia cardiaca. Revista Española de Cardiología 2015;68:885-91. [DOI: 10.1016/j.recesp.2015.05.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
5 Greenberg B. Mineralocorticoid receptor antagonists in heart failure: they work better when patients use them. Eur J Heart Fail 2018;20:1335-7. [PMID: 29851224 DOI: 10.1002/ejhf.1222] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Vizzardi E, Sciatti E, Bonadei I, D'Aloia A, Tartière-Kesri L, Tartière JM, Cohen-Solal A, Metra M. Effects of spironolactone on ventricular-arterial coupling in patients with chronic systolic heart failure and mild symptoms. Clin Res Cardiol 2015;104:1078-87. [PMID: 26058790 DOI: 10.1007/s00392-015-0877-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
7 Böhm M, Ewen S. Blood Pressure Risk Associations in Heart Failure. JACC: Heart Failure 2017;5:820-2. [DOI: 10.1016/j.jchf.2017.09.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
8 Smeets M, Vaes B, Aertgeerts B, Raat W, Penders J, Vercammen J, Droogne W, Mullens W, Janssens S. Impact of an extended audit on identifying heart failure patients in general practice: baseline results of the OSCAR-HF pilot study. ESC Heart Fail 2020. [PMID: 32969599 DOI: 10.1002/ehf2.12990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Franke J, Lindmark A, Hochadel M, Zugck C, Koerner E, Keppler J, Ehlermann P, Winkler R, Zahn R, Katus HA, Senges J, Frankenstein L. Gender aspects in clinical presentation and prognostication of chronic heart failure according to NT-proBNP and the Heart Failure Survival Score. Clin Res Cardiol 2015;104:334-41. [PMID: 25373384 DOI: 10.1007/s00392-014-0786-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
10 Frankenstein L, Fröhlich H, Cleland JG. Multidisciplinary Approach for Patients Hospitalized With Heart Failure. Rev Esp Cardiol (Engl Ed) 2015;68:885-91. [PMID: 26409892 DOI: 10.1016/j.rec.2015.05.008] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Böhm M, Tschöpe C, Wirtz JH, Lokies J, Turgonyi E, Bramlage P, Lins K, Strunz AM, Tebbe U. Treatment of heart failure in real-world clinical practice: findings from the REFLECT-HF registry in patients with NYHA class II symptoms and a reduced ejection fraction. Clin Cardiol 2015;38:200-7. [PMID: 25733185 DOI: 10.1002/clc.22375] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
12 Vukadinović D, Lavall D, Vukadinović AN, Pitt B, Wagenpfeil S, Böhm M. True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis. Am Heart J 2017;188:99-108. [PMID: 28577687 DOI: 10.1016/j.ahj.2017.03.011] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 8.2] [Reference Citation Analysis]
13 El Hadidi S, Vaughan C, Kerins D, Byrne S, Darweesh E, Bermingham M. Guideline-led prescribing to ambulatory heart failure patients in a cardiology outpatient service. Int J Clin Pharm 2021;43:1082-9. [PMID: 33411177 DOI: 10.1007/s11096-020-01220-z] [Reference Citation Analysis]
14 Guenther M, Kolschmann S, Knaut M. Substernal lead implantation: a novel option to manage DFT failure in S-ICD patients. Clin Res Cardiol 2015;104:189-91. [DOI: 10.1007/s00392-014-0764-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
15 Ewen S, Mahfoud F, Böhm M. Chronische Herzinsuffizienz: Aktuelle Leitlinienempfehlungen und neue Erkenntnisse. Internist 2015;56:791-802. [DOI: 10.1007/s00108-015-3703-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
16 Hirt MN, Muttardi A, Helms TM, van den Bussche H, Eschenhagen T. General practitioners' adherence to chronic heart failure guidelines regarding medication: the GP-HF study. Clin Res Cardiol 2016;105:441-50. [DOI: 10.1007/s00392-015-0939-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
17 Störk S, Handrock R, Jacob J, Walker J, Calado F, Lahoz R, Hupfer S, Klebs S. Treatment of chronic heart failure in Germany: a retrospective database study. Clin Res Cardiol 2017;106:923-32. [PMID: 28748266 DOI: 10.1007/s00392-017-1138-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
18 Sarwar CM, Papadimitriou L, Pitt B, Piña I, Zannad F, Anker SD, Gheorghiade M, Butler J. Hyperkalemia in Heart Failure. J Am Coll Cardiol 2016;68:1575-89. [PMID: 27687200 DOI: 10.1016/j.jacc.2016.06.060] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 11.6] [Reference Citation Analysis]
19 Böhm M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Mahfoud F, Brueckmann M, Jamal W, Ofstad AP, Schüler E, Ponikowski P, Wanner C, Zannad F, Packer M; EMPEROR-Reduced Trial Committees and Investigators. Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. J Am Coll Cardiol 2021;78:1337-48. [PMID: 34556320 DOI: 10.1016/j.jacc.2021.07.049] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Beygui F, Anguita M, Tebbe U, Comin-colet J, Galinier M, Bramlage P, Turgonyi E, Lins K, Imekraz L, de Frutos T, Böhm M. A real-world perspective on the prevalence and treatment of heart failure with a reduced ejection fraction but no specific or only mild symptoms. Heart Fail Rev 2015;20:545-52. [DOI: 10.1007/s10741-015-9496-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
21 Zannad F, Rossignol P, Stough WG, Epstein M, Alonso Garcia MDLA, Bakris GL, Butler J, Kosiborod M, Berman L, Mebazaa A, Rasmussen HS, Ruilope LM, Stockbridge N, Thompson A, Wittes J, Pitt B. New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. International Journal of Cardiology 2016;216:46-51. [DOI: 10.1016/j.ijcard.2016.04.127] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
22 Wang AY. Optimally managing hyperkalemia in patients with cardiorenal syndrome. Nephrol Dial Transplant 2019;34:iii36-44. [PMID: 31800079 DOI: 10.1093/ndt/gfz225] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Osmolovskaya YF, Zhirov IV, Tereshchenko SN. [Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015]. Ter Arkh 2015;87:77-83. [PMID: 26591557 DOI: 10.17116/terarkh201587977-83] [Reference Citation Analysis]
24 Smeets M, Vaes B, Mamouris P, Van Den Akker M, Van Pottelbergh G, Goderis G, Janssens S, Aertgeerts B, Henrard S. Burden of heart failure in Flemish general practices: a registry-based study in the Intego database. BMJ Open 2019;9:e022972. [PMID: 30617099 DOI: 10.1136/bmjopen-2018-022972] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
25 Ewen S, Bohm M. Too much is too much: evidence against dual RAAS inhibition in hypertensives with heart failure symptoms. European Heart Journal 2015;36:899-901. [DOI: 10.1093/eurheartj/ehv033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]